Scientific and Regulatory Procedures: Use of Dogs

John Milne Excerpts

Monday 28th April 2025 Westminster Hall

[John Milne (Horsham) (LD)]

It is a pleasure to serve under your chairmanship today, Ms Jardine. I am grateful to speak in this very important debate. Every year, thousands of dogs are subjected to scientific experiments in the UK, often in the name of drug development. For many this raises serious ethical questions about the use of animals for human gain. Is an animal’s suffering worth the benefits to scientific discovery? For others, science and not the animals are paramount; the end justifies the means, as it were. However, animal testing does not deliver robust and useful scientific data. In fact, drug research on dogs tells us very little about whether a drug will work for humans, so campaigners argue that it is time to end animal research.

Dr Jarrod Bailey, a geneticist, put it plainly: different species react differently to diseases and treatments. In other words, what works in dogs might not work in humans. In fact, drugs that pass animal tests fail in human trials 92% of the time—a staggering and costly statistic. In toxicity testing, even when dogs show no toxic response it barely improves our confidence that the drug will be safe in humans. It improves it from 70% to just 72%, which is barely noticeable. Is that really a sound basis for human medicine?

Fortunately, science offers us a better path forward. Human-specific technologies such as organ chips are revolutionising drug development. Those miniaturised organs mimic how real human organs react to treatments and can be patient-specific. They have shown 87% accuracy in detecting drug-induced liver toxicity, which is a dramatic improvement over animal models. If adopted widely, these tools could create over $24 billion through research and development in the US. The US Food and Drug Administration has recognised that. Through the FDA Modernisation Act 2.0, the agency has removed the legal requirement for animal testing in drug trials. A third Act is already in the works to accelerate the validation and adoption of human-specific methods such as organ chips.

In the UK we are lagging behind, not because of legal barriers, but perhaps because of entrenched industry habits, financial interests or even cultural resistance in the research community. We can change that—gradually, responsibly and strategically. I am calling for a phased approach to end the use of dogs in UK research. That means increased investment in modern human-relevant alternatives and a national commitment to shifting away from outdated animal models. When the practice of animal testing is scientifically flawed, it is also undeniably ethically indefensible. Animal suffering for unreliable and inapplicable data cannot be justified when we have the tools and knowledge to do better. Let the UK be a leader, not a follower, in creating a more humane and effective future for our scientific research.